Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: activity test.
- Who it may be relevant to
- Registry conditions: Cannabis User. Basic parameters: 18 years — 35 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.
Interventions
- Other activity test
Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
Primary outcome measures
- Plasma endocannabinoids levels (pmol/ml) [Time frame: 2 weeks]
Secondary outcome measures (5)
- regulating hormone of endocannabinoids (plasma levels of cortisol, ng/ml) [Time frame: 2 weeks]
- Blood marker of neurogenesis and neuroplasticity (plasma levels and BDNF, pg/ml) [Time frame: 2 weeks]
- change in cerebral muscular, oxygenation (HHB), (HbO2), (Hbtot) (arbitrary unit) [Time frame: 2 weeks]
- Cognitive function (selective attention, stroop test) [Time frame: 2 weeks]
- Oxygen consumption (VO2) (ml/min/kg) [Time frame: 2 weeks]
Eligibility criteria
Inclusion criteria
Cannabis consumer group:
- Cannabis consumption > 100 times in lifetime, last exposure < 7 days, and recent exposure > 10 times in the month.
- Positive toxicological urine test for ∆-9-THC.
- Having a cannabis use disorder according to the CAST.
Healthy group:
- Negative urine toxicological test for cannabis.
- No regular cannabis use for more than 6 months once in a lifetime.
- No cannabis consumption in the 6 months preceding the study.
Exclusion criteria
For all subjects :
- Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs).
- Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit.
- Under medical treatment.
- Presence of diagnosed neurological disorders.
- Diagnosis of a psychotic picture entering axis I, DSM-5.
- Chronic progressive disease or in remission.
- Body mass index > 30 kg/m2 (i.e. presence of obesity).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Other
Study locations
France · 1 center
- CHU Lille — Lille
Identifiers
NCT: NCT06081218 · 2016_70